Citations

Showing 10 of 108152 citations.

Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) Reveals Improvements in the Treatment of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae in Patients from the Veterans Health A
Pérez, Federico , Wilson, Brigid , Saade, Elie , Jump, Robin , Banerjee, Ritu , Patel, Robin , Patel, Robin , Evans, Scott R , Saade, Elie , Viau, Roberto A. , Evans, Scott , Bonomo, Robert A.

Mayo Clinic

Clinical Infectious Diseases | May 7, 2021 | Volume: 73 | Issue: 7 | Pages: 1231-1238

10.1093/cid/ciab384 | PMID 33978146 Get It

Abstract Background Reductions in the use of broad-spectrum antibiotics is a cornerstone of antimicrobial stewardship. We aim to demonstrate use of the Desirability of Outcome Ranking Approach for the Management of Antimicrobial Therapy (DOOR MAT) to evaluate the treatment of Escherichia coli and Klebsiella pneumoniae bloodstream infections in patients from the Veterans Health Administration (VHA) across a decade. Methods Using electronic records, we determined empiric and definitive antibiotic treatments, clinical characteristics, and 30-day mortality of patients with monomicrobial E. coli and K. pneumoniae bloodstream infections hospitalized in VHA medical centers from 2009 to 2018. Focusing on patients treated with parenteral β-lactams and with available antibiotic susceptibility testing results, we applied a range of DOOR MAT scores that reflect the desirability of antibiotic choices according to spectrum and activity against individual isolates. We report trends in resistance and desirability of empiric and definitive antibiotic treatments. Results During the 10-year period analyzed, resistance to expanded-spectrum cephalosporins and fluoroquinolones increased in E. coli but not in K. pneumoniae, while resistance to carbapenems and piperacillin-tazobactam remained unchanged. In 6451 cases analyzed, we observed improvements in DOOR MAT scores consistent with deescalation. Improvement in desirability of definitive treatment compared with empiric treatment occurred in 26% of cases, increasing from 16% in 2009 to 34% in 2018. Reductions in overtreatment were sustained and without negative impact on survival. Conclusions DOOR MAT provides a framework to assess antibiotic treatment of E. coli and K. pneumoniae bloodstream infections and can be a useful metric in antimicrobial stewardship.
Venous Information in CT-Based Stroke Selection
Leslie‐Mazwi, Thabele M , Lin, Michelle

Mayo Clinic

Neurology | May 7, 2021 | Volume: 96 | Issue: 24 | Pages: 1109-1110

10.1212/wnl.0000000000012126 | PMID 33952653 Get It

Autologous Fat Grafting Does Not Increase Risk of Oncologic Recurrence in the Reconstructed Breast
Shrout, Max A., DeCoster, Ryan , Burns, Jack C., Rodgers, Louis C., Mercer, James P., Rinker, Brian, Vásconez, Henry C., Vyas, Krishna S.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 6, 2021 | Volume: 8 | Issue: 7S | Pages: 3-3

10.1097/01.gox.0000695988.90253.43 Get It

Medicare Reimbursement Trends for Reconstructive Plastic Surgery Procedures
Thornburg, Danielle A. , Haglin, Jack M. , Casey, William J., Gupta, Nikita

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 6, 2021 | Volume: 8 | Issue: 7S | Pages: 9-9

10.1097/01.gox.0000696040.03631.5a Get It

First Case Report of a Navajo Indian Patient with Morbihan’s Disease: Insight into Oculoplastic Treatment of a Rare Disease
Rochin, Ana Elizabeth Meza, Decapite, Tim, Mansueto, Lisa A., Pflibsen, Lacey R.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 6, 2021 | Volume: 8 | Issue: 7S | Pages: 8-9

10.1097/01.gox.0000696036.39137.1d Get It

Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey
Martelletti, Paolo , Vo, Pamela, Ritrovato, Daniela , Reilly, Margaret C., Naclerio, Mariantonietta , Ranjan, Pallavi, Kleebach, Joern, Joshi, Parth, Schwedt, Todd J. , Ranjan, Pallavi

Mayo Clinic

Journal of Medical Economics | May 6, 2021 | Volume: 24 | Issue: 1 | Pages: 717-726

10.1080/13696998.2021.1925557 | PMID 33955821 Get It

Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly
Bacha, Dania S. , Rahme, Maya , Al‐Shaar, Laila , Halaby, Georges, Mahfoud, Ziyad , Habib, Robert, Arabi, Asma , Fuleihan, Ghada El‐Hajj , El-Hajj Fuleihan, Ghada , Baddoura, Rafic , Singh, Ravinder J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 6, 2021 | Volume: 106 | Issue: 9 | Pages: e3644-e3654

10.1210/clinem/dgab296 | PMID 33954783 Get It

Abstract Context Guidelines for the dosage of vitamin D supplementation vary widely globally. Objective To investigate the impact of 2 vitamin D doses, bracketed between the IOM recommended dietary allowance (RDA) and the upper tolerable limit, on vitamin D nutritional status in elderly individuals. Methods This post hoc analysis of data collected from a 12-month, double-blind, randomized control trial included 221 ambulatory participants (≥ 65 years) with a mean BMI of 30.2 kg/m2 and a mean baseline serum 25-hydroxyvitamin D [25(OH)D] level of 20.4 ± 7.4 ng/mL, who were recruited from 3 outpatient centers in Lebanon. All participants received 1000 mg of elemental calcium daily from calcium citrate plus the daily equivalent of either 600 IU or 3750 IU of vitamin D3. Results Mean 25(OH)D level at 12 months was 26.0 ng/mL with low dose and 36.0 ng/mL with high dose vitamin D3. The proportion of participants reaching a value ≥ 20 ng/mL was 86% in the low dose, and 99% in the high dose arms, with no gender differences. The increment of 25(OH)D per 100 IU/day was 1 ng/mL with the low dose, and 0.41 ng/mL with the high dose. Serum 25(OH)D levels at 1 year were highly variable in both treatment arms. Baseline 25(OH)D level and vitamin D dose—but not age, BMI, gender, or season—were significant predictors of serum 25(OH)D level post-intervention. Conclusion The IOM Recommended Dietary Allowance (RDA) of 600 IU/day does not bring 97.5% of ambulatory elderly individuals above the desirable threshold of 20 ng/mL. Country-specific RDAs are best derived taking into account the observed variability and predictors of achieved 25(OH)D levels.
Flow Cytometric Evaluation of Surface and Cytoplasmic TRBC1 Expression in the Differential Diagnosis of Immature T-Cell Proliferations
Otteson, Gregory E., Shi, Min , Jevremović, Dragan , Ji, Yuan , Olteanu, Horatiu , Horna, Pedro , Shi, Min , Jevremovic, Dragan , Olteanu, Horatiu , Yuan, Ji

Mayo Clinic

American Journal of Clinical Pathology | May 6, 2021 | Volume: 157 | Issue: 1 | Pages: 64-72

10.1093/ajcp/aqab098 | PMID 34302330 Get It

Abstract Objectives Flow cytometric detection of T-cell clonality is challenging, particularly in differential diagnosis of immature T-cell proliferations. Studies have shown utility of TRBC1, in conjunction with other T-cell markers, as reliable means to identify T-cell clonality by flow cytometry. One limitation of surface TRBC1 (sTRBC1) evaluation is it cannot be detected in surface CD3 (sCD3)-negative T cells, such as normal or abnormal immature T-cell precursors. Here, we assess surface and cytoplasmic TRBC1 expression patterns in the differential diagnosis of T-lymphoblastic leukemia/lymphoma (T-ALL) vs normal thymocyte expansions. Methods Forty-three samples containing T-ALL, thymoma, normal thymus, and/or indolent T-lymphoblastic proliferation (i-TLBP), were evaluated. Results All 24 cases with normal thymocytes or i-TLBPs revealed a characteristic and reproducible sCD3/sTRBC1 expression pattern indicative of polytypic T-cell maturation. In contrast, all 19 T-ALLs lacked this polytypic maturation pattern and were either completely negative for sCD3/sTRBC1 or showed a minor sCD3-positive subset with a monotypic TRBC1 expression pattern. Cytoplasmic TRBC1 evaluation in 9 T-ALLs demonstrated a monotypic intracellular TRBC1-positive (n = 4) or TRBC1-negative (n = 5) expression, indicative of clonality. Conclusions Our findings demonstrate flow cytometric evaluation of surface and cytoplasmic TRBC1 expression can aid detection of T-cell clonality and differential diagnosis of immature T-cell proliferations.
Clinical Outcomes of Critically Ill Patients Using Inhaled Nitric Oxide (iNO) during Intrahospital Transport
Koyfman, Leonid, Simchon, Omri, Koyfman, Anna , Mushaev, Shoshana, Gruenbaum, Benjamin F. , Gal, Ron, Friger, Michael , Arotsker, Natan, Klein, Moti, Brotfain, Evgeni , Brotfain, Evgeni , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

Critical Care Research and Practice | May 6, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-6

10.1155/2021/6633210 | PMID 34035958 Get It

Critically ill patients with severe hypoxemia are often treated in the intensive care unit (ICU) with inhaled nitric oxide (iNO). These patients are at higher risk when they require intrahospital transportation. In this study, we collected clinical and laboratory data from 221 patients who were hospitalized in the general ICU and treated with iNO at Soroka Medical Center, Israel, between January 2010 and December 2019. We retrospectively compared the 65 patients who received iNO during intrahospital transportation to the 156 patients who received iNO without transportation. Among critically ill patients who were transported while being administered iNO, only one patient had an adverse event (atrial fibrillation) on transport. We found that maximal iNO dosage during ICU stay, duration of mechanical ventilation, and percent of vasopressor support were the only independent risk factors for ICU mortality in both study groups. No difference in primary outcome of ICU mortality rate was found between the critically ill patients treated with iNO during intrahospital transportation and those who were treated with iNO but not transported during the ICU stay. We anticipate that this study will advise clinical decision-making in the ICU, especially when treating patients who are administered iNO.
Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
Usón, Pedro Luiz Serrano , Nagalo, Bolni Marius , Ahn, Daniel H. , Bekaii‐Saab, Tanios , Uson Junior, Pedro Luiz Serrano, Uson, Pedro L S , Bekaii-Saab, Tanios S , Nagalo, Bolni , Borad, Mitesh J.

Mayo Clinic

Seminars in Liver Disease | May 6, 2021 | Volume: 41 | Issue: 02 | Pages: 136-141

10.1055/s-0040-1722646 | PMID 33957697 Get It

Abstract The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.